2010
DOI: 10.5581/1516-8484.20110029
|View full text |Cite
|
Sign up to set email alerts
|

Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros

Abstract: BackgroundThe development of therapies for sickle cell disease has received special attention, particularly those that reduce the polymerization of hemoglobin S. Hydroxyurea is a commonly used medication because it has the ability to raise levels of fetal hemoglobin, decrease the frequency of vaso-occlusive episodes and thus improve the clinical course of sickle cell disease patients.ObjectiveTo study hematological data and the clinical profile of sickle cell disease patients taking hydroxyurea in a regional b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

3
0
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 19 publications
(26 reference statements)
3
0
0
Order By: Relevance
“…As expected, in contrast to SCA patients who did not receive HU, those who received this treatment presented increased HbF levels and improvements in hemolytic, hepatic and inflammatory profiles (hemoglobin, hematocrit, MCV, MCH, reticulocytes, MCHC, RDW, AST, total bilirubin, LDH, WBC, neutrophils, eosinophils, lymphocytes, monocytes, platelets, and plateletcrit). These findings corroborate previous studies, which also demonstrated improvements in hemolytic, hepatic and inflammatory profiles in patients with SCA undergoing HU therapy (de Souza Santos and Maia, 2010;Voskaridou et al, 2010;de Souza Torres et al, 2012;Pallis et al, 2014;Belini Junior et al, 2015;Shome et al, 2016;Quarmyne et al, 2017;Colombatti et al, 2018). We further observed an increase in HDL-C concentration, demonstrating the effect of HU on lipid metabolism, which is consistent with our previous results (Yahouedehou et al, 2018b;Yahouedehou et al, 2019).…”
Section: Discussionsupporting
confidence: 93%
“…As expected, in contrast to SCA patients who did not receive HU, those who received this treatment presented increased HbF levels and improvements in hemolytic, hepatic and inflammatory profiles (hemoglobin, hematocrit, MCV, MCH, reticulocytes, MCHC, RDW, AST, total bilirubin, LDH, WBC, neutrophils, eosinophils, lymphocytes, monocytes, platelets, and plateletcrit). These findings corroborate previous studies, which also demonstrated improvements in hemolytic, hepatic and inflammatory profiles in patients with SCA undergoing HU therapy (de Souza Santos and Maia, 2010;Voskaridou et al, 2010;de Souza Torres et al, 2012;Pallis et al, 2014;Belini Junior et al, 2015;Shome et al, 2016;Quarmyne et al, 2017;Colombatti et al, 2018). We further observed an increase in HDL-C concentration, demonstrating the effect of HU on lipid metabolism, which is consistent with our previous results (Yahouedehou et al, 2018b;Yahouedehou et al, 2019).…”
Section: Discussionsupporting
confidence: 93%
“…Laboratory marker analysis showed significant increase in MCV and MCH in the SCA-HU + group compared to the SCA-HU − group. This corroborates the report of Santos and Maia [33] which found significant change in MCV and MCH in individuals with SCA under HU therapy. HbF has been recognized as among the most important known modifiers of the clinical course of SCD.…”
Section: Discussionsupporting
confidence: 93%
“…On the other hand, the females reported higher rates of severe painful episodes, VOCs, and hospitalization in comparison to their male counterparts according to an observational study that analyzed data of 2124 patients from Sickle Cell Disease Implementation Consortium (SCDIC) registry [ 28 ]. The reticulocyte counts have been significantly decreased after the initiation of HU treatment, which is consistent with the preponderance of evidence [ 21 , 29 ].…”
Section: Discussionsupporting
confidence: 85%